The Bcl-2 family proteins that control homeostasis of cells play an important role in apoptosis. This group consists of antiapoptotic (Bcl-2, Bcl-XL) and proapoptotic (Bcl-2 associated protein X, Bax; B-cell homologous antagonist/killer, Bak) molecules. In the thyroid, abnormal apoptotic activity may be involved in a variety of diseases such as autoimmune thyroid diseases. The aim of the current study was to estimate the expression of pro- and antiapoptotic proteins in thyroid tissues from young patients with Graves’ disease (GD), nontoxic nodular goiter and toxic nodular goiter using Western Blot and immunohistochemistry. Identification of the antiapoptotic Bcl-2 and Bcl-XL molecules in the thyrocytes revealed higher expression of both proteins in patients with GD (assessed as +++/++ and ++/+, respectively). In adolescents with toxic and nontoxic nodular goiter, this expression was lower (Bcl-2 ++/+ , ++/+; Bcl-XL +, +). The tissue material was additionally subjected to Western Blot analysis, which in GD patients showed the presence of Bcl-2 and Bcl-XL in one band p26 kDa. In patients with toxic and nontoxic nodular goiter, the intensity of expression for these two antiapoptotic proteins was lower (referred to band 26 kDa for Bcl-2 and Bcl-XL). Identification of the proapoptotic proteins Bax and Bak revealed their predominance in thyrocytes of GD patients (+, ++/+, respectively) as compared to patients with toxic and nontoxic nodular goiter (0/+, 0/+ for Bax and 0/+, 0/+ for Bak). In GD patients, Western Blot analysis showed Bax expression in one band 21 kDa and Bak in two bands p50, p24 kDa. In patients with nodular goiter, the degree of expression of both proapoptotic proteins was lower and referred to band 21 kDa for Bax (toxic and nontoxic goiter) and 24 kDa for Bak (toxic goiter only). Patients with GD showed a statistically significant correlation between Bcl-2 expression and antibodies against receptor for thyroid stimulating hormone (R = 0.47, p < 0.03); however, such a correlation was not observed in patients with nodular goiter. In conclusion, our findings suggest that the changes in the expression of regulatory proteins of the Bcl-2 family in the thyroid follicular cells indicate the involvement of apoptosis in the pathogenesis of GD.

Kawakami A, Eguchi K: Involvement of apoptotic cell death in autoimmune diseases. Med Electron Microsc 2002;35:1–8.
Bossowski A, Moniuszko A, Boużyk J, Urban M: Role of apoptosis in autoimmune thyroid diseases. Endocrinol Diabetol Metabol Dis Dev Age 2006;12:216–220.
Hengartner MO: The biochemistry of apoptosis. Nature 2000;407:770–776.
Salvesen GS, Dixit VM: Caspases: intracellular signaling by proteolysis. Cell 1997;91:443–446.
Kroemer G, Zamzami N, Susin SA: Mitochondria control of apoptosis. Immunol Today 1997;18:44–51.
Green DR, Reed JC: Mitochondria and apoptosis. Science 1998;281:1309–1312.
Kroemer G: The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med 1997;3:614–620.
Palazzo FF, Hammond LJ, Goode AW, Mirakian R: Death of the autoimmune thyrocyte: is it pushed or does it jump? Thyroid 2000;10:561–572.
Hammond LJ, Lowdell MW, Cerrano PG, Goode AW, Bottazzo GF, Mirakian R: Analysis of apoptosis in relation to tissue destruction associated with Hashimoto’s autoimmune thyroiditis. J Pathol 1997;182:138– 144.
Hiromatsu Y, Kaku H, Mukai T: Immunohistochemical analysis of Bcl-2, Bax and Bak expression in thyroid glands from patients with Graves’ disease. Endocr J 2004;51:399–405.
Adams J.M, Cory S: Life-or-death decisions by the Bcl-2 protein family. Trends Biochem Sci 2001;26:61–66.
Gross A, Yin XM, Wang K, Wei MC, Jockel J, Milliman C, Erdjument-Bromage H, Tempst P, Korsmeyer SJ: Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death. J Biol Chem 1999;274:1156–1163.
Hu Y, Benedict MA, Wu D, Inohara N, Nunez G: Bcl-XL interacts with Apaf-1 and inhibits Apaf-1-dependent caspase-9 activation. Proc Natl Acad Sci USA 1998;95:4386–4391.
Pan G, O’Rourke K, Dixit VM: Caspase-9, Bcl-XL and Apaf-1 form a ternary complex. J Biol Chem 1998;273:5841–5845.
Reed JC: Double identity for protein of the Bcl-2 family. Nature 1997;387:773–776.
Roura-Mir C, Catalfamo M, Sospedra M, Alcalde L, Pujol-Borrell R, Jaraquemada D: Single-cell analysis of intrathyroidal lymphocytes shows differential cytokine expression in Hashimoto’s thyroiditis and Graves’ disease. Eur J Immunol 1997;27:3290–3302.
Vella V, Mineo R, Frasca F, Mazzon E, Pandini G, Vigneri R, Belfiore A: Interleukin-4 stimulates thyroid cancer cell survival: implications in patients with thyroid cancer and concomitant Graves’ disease. J Clin Endocrinol Metab 2004;89:2880–2889.
De la Vega JR, Vilaplana JC, Biro A, Hammand L, Bottazzo GF, Mirakian R: IL-10 expression in thyroid glands: protective or harmful role against thyroid autoimmunity? Clin Exp Immunol 1998;113:126–135.
Riou C, Tonoli H, Bernier-Valentin F, Rabilloud R, Fonlupa P, Rousset B: Susceptibility of differentiated thyrocytes in primary culture to undergo apoptosis after exposure to hydrogen peroxide: relation with the level of expression of apoptosis regulatory proteins, Bcl-2 and Bax. Endocrinology 1999;140:1990–1997.
Andrikoula M, Vartholomatos G, Tsangaris GT, Bafa M, Tzortzatou-Stathopoulou F, Tsatsoulis A: Fas and Bcl-2 protein expression in thyrocytes of patients with nodular goiter. Eur J Endocrinol 2001;145:403–407.
Labat-Moleur F, Chabre O, Guillermet C, Chaffanjon P, Blumet-Rondeu F, Bauchet A, Franc B, Brambilla E, Bachelot I, Dumont JE, Negoescu A: Graves-Basedow disease goiter: a model of Bax-Bcl-2 regulated apoptosis. Thyroid 1999;9:483–492.
Yehuda-Shnaidman E, Kalderon B, Bar-Tana J: Modulation of mitochondrial transition pore components by thyroid hormone. Endocrinology 2005;146:2462–2472.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.